mCureX Therapeutics, Inc.
Pharmaceuticals, focuses on the research and development of mRNA (messenger RNA) vaccines and therapeutics.
Pharmaceuticals, focuses on the research and development of mRNA (messenger RNA) vaccines and therapeutics.
mCureX Therapeutics, Inc. is a subsidiary of OliX Pharmaceuticals, specializing in the research and development of mRNA vaccines and therapeutics. The company has proprietary technology and expertise in preclinical and clinical development, as well as production know-how for designing mRNA molecular structures. Utilizing modified nucleotide technology with secured FTO, mCureX has selected lead candidates for COVID-19 vaccines and commenced production. Positioned as a pioneer in the mRNA therapeutics and vaccines market, the company plans to expand its pipeline to address various indications, including infectious diseases such as influenza, cancer, respiratory, and liver diseases. Founded in 2021, mCureX aspires to be a frontrunner in the pharmaceutical industry, leveraging its innovative mRNA platform to make significant advancements in healthcare. Stay tuned for the milestones that mCureX, the messenger for cure, is set to achieve.
There is no investment information
No recent news or press coverage available for mCureX Therapeutics, Inc..
We care about your data, and we'd love to use cookies make your experience better.